WO2009152483A3 - Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma - Google Patents

Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma Download PDF

Info

Publication number
WO2009152483A3
WO2009152483A3 PCT/US2009/047288 US2009047288W WO2009152483A3 WO 2009152483 A3 WO2009152483 A3 WO 2009152483A3 US 2009047288 W US2009047288 W US 2009047288W WO 2009152483 A3 WO2009152483 A3 WO 2009152483A3
Authority
WO
WIPO (PCT)
Prior art keywords
nitric oxide
nervous system
central nervous
trauma
therapy
Prior art date
Application number
PCT/US2009/047288
Other languages
French (fr)
Other versions
WO2009152483A2 (en
Inventor
Amy Bishop
Original Assignee
University Of Alabama Huntsville
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Alabama Huntsville filed Critical University Of Alabama Huntsville
Publication of WO2009152483A2 publication Critical patent/WO2009152483A2/en
Publication of WO2009152483A3 publication Critical patent/WO2009152483A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed herein are methods for treating Central Nervous System (CNS) diseases and CNS injuries. The methods provide to cells an amount of nitric oxide that induces in the cells an adaptive resistance to high levels of nitric oxide which are destructive and which are associated with diseases of the Central Nervous System, inter alia, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease and diabetic neuropathy. Also disclosed are methods for determining a therapeutically effective amount of nitric oxide. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
PCT/US2009/047288 2008-06-12 2009-06-12 Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma WO2009152483A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6096908P 2008-06-12 2008-06-12
US61/060,969 2008-06-12

Publications (2)

Publication Number Publication Date
WO2009152483A2 WO2009152483A2 (en) 2009-12-17
WO2009152483A3 true WO2009152483A3 (en) 2012-05-18

Family

ID=41417417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047288 WO2009152483A2 (en) 2008-06-12 2009-06-12 Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma

Country Status (1)

Country Link
WO (1) WO2009152483A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234956A (en) * 1991-04-19 1993-08-10 The Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US20070129336A1 (en) * 2003-03-27 2007-06-07 Inologic, Inc. Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
US20070196327A1 (en) * 2005-12-06 2007-08-23 Amulet Pharmaceuticals, Inc. Nitric oxide releasing polymers
US20080069904A1 (en) * 2006-07-18 2008-03-20 Oronsky Bryan T Inhibition of angiogenesis through nitric oxide tachyphylaxis
US20080260797A1 (en) * 2007-04-18 2008-10-23 Oh-Lee Justin D Methods of treating disease with nitric oxide (no)-releasing polymers and soluble no-releasing nitrosamines
US20090143417A1 (en) * 2004-12-24 2009-06-04 The University Of Queensland Methods of treating pain

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234956A (en) * 1991-04-19 1993-08-10 The Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
US6436996B1 (en) * 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US20070129336A1 (en) * 2003-03-27 2007-06-07 Inologic, Inc. Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
US20090143417A1 (en) * 2004-12-24 2009-06-04 The University Of Queensland Methods of treating pain
US20070196327A1 (en) * 2005-12-06 2007-08-23 Amulet Pharmaceuticals, Inc. Nitric oxide releasing polymers
US20080069904A1 (en) * 2006-07-18 2008-03-20 Oronsky Bryan T Inhibition of angiogenesis through nitric oxide tachyphylaxis
US20080260797A1 (en) * 2007-04-18 2008-10-23 Oh-Lee Justin D Methods of treating disease with nitric oxide (no)-releasing polymers and soluble no-releasing nitrosamines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BISHOP ET AL.: "Adaptive Resistance to Nitric Oxide in Motor Neurons.", FREE RADICAL BIOLOGY & MEDICINE, vol. 26, no. 7-8, 1999, pages 978 - 986 *

Also Published As

Publication number Publication date
WO2009152483A2 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
EA201300975A1 (en) NEW COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
BR112012013038A2 (en) antibody fc mutants with ablated effector functions
WO2009127642A3 (en) Use of lrrk2 inhibitors for neurodegenerative diseases
WO2005099716A3 (en) Method for analyzing the biological age of a subject
WO2008048514A3 (en) Topical nitric oxide as a treatment of autoimmune diseases
WO2007009083A3 (en) Compounds with activity at retinoic acid receptors
WO2008129023A3 (en) Oligonucleotide compositions for the treatment of alzheimer&#39;s disease
WO2013030778A3 (en) Organic compositions to treat hsf1-related diseases
WO2010017436A3 (en) Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides
WO2007064882A3 (en) Treatment of conditions involving demyelination
WO2006012641A3 (en) Methods for detecting and treating autoimmune disorders
TNSN08205A1 (en) Use of a cb1 antagonist for treating negative symptoms of schizophrenia
EP1969003B8 (en) Uses of a NEUROTROPHIC FACTOR PROTEIN
NZ596366A (en) Enhanced immune response in avian species
MX2009008846A (en) Methods for treating diseases of altered ige regulation.
WO2010041252A3 (en) Use of a cinnamon bark extract for treating amyloid-associated diseases
WO2010129665A3 (en) Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
WO2007133983A3 (en) 2-aminobenzimidazoles for treating neurodegenerative diseases
MX2010005205A (en) Active soluble post-translationally modified neuregulin isoforms.
WO2012177831A3 (en) Compounds for treating peripheral neuropathies and other neurodegenerative disorders
WO2009152483A3 (en) Nitric oxide induced adaptive resistance as a therapy for central nervous system diseases and trauma
WO2009048917A3 (en) Increased fiber hydrolysis by protease addition
WO2007008904A3 (en) Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
WO2009117373A3 (en) Treatment and prevention of gardnerella vaginalis infections
WO2008097971A3 (en) Methods for treating diseases of altered ige regulation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09763771

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09763771

Country of ref document: EP

Kind code of ref document: A2